AGC Biologics

SHERIDAN, WYOMING - April 10, 2026 - AGC Biologics has tied an expansion of microbial manufacturing capacity at its Heidelberg facility to a limited-time commercial offer for late-phase and commercial drug developers. The company said it is offering VIP priority slots and set pricing for 10,000 L GMP production, positioning the package as a way to secure supply and reduce exposure to delays. For biopharma companies moving toward launch or scale-up, the development matters because capacity access, price visibility and site selection can materially affect supply planning, regulatory execution and commercial readiness.

SHERIDAN, WYOMING - April 04, 2026 - Biopharmaceutical developers advancing late-phase and commercial microbial programs now face compounding risks from tariff volatility, supply chain fragility, and GMP slot scarcity - pressures that are reshaping how sponsors select and lock in CDMO partnerships heading into 2026 budget cycles.

Heidelberg capacity expansion and the VIP slot offer

AGC Biologics is expanding microbial manufacturing capacity at its Heidelberg facility and has opened a limited window of priority GMP slots for 10,000 L production runs at set pricing with pre-determined timelines. The offer targets late-phase and commercial developers who need to secure supply against market volatility and scheduling uncertainty. Terms and conditions apply, and the window is explicitly time-limited.